{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:21:52Z","timestamp":1770733312968,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1124\/dmd.109.027656","type":"journal-article","created":{"date-parts":[[2009,4,28]],"date-time":"2009-04-28T01:05:47Z","timestamp":1240880747000},"page":"1395-1403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters"],"prefix":"10.1016","volume":"37","author":[{"given":"Andrew","family":"Rowland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Knights","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.109.027656_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1020520521025","article-title":"Intracellular lipid binding proteins of the small intestine","volume":"239","author":"Agellon","year":"2002","journal-title":"Mol Cell Biochem"},{"key":"10.1124\/dmd.109.027656_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigation with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","article-title":"Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen","volume":"60","author":"Bowalgaha","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/dmd.106.011569","article-title":"Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance","volume":"35","author":"Brown","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.027656_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03194597","article-title":"The multi-gene family of fatty acid binding proteins (FABPs): function, structure and polymorphism","volume":"47","author":"Chmurzy\u0144ska","year":"2006","journal-title":"J Appl Genet"},{"key":"10.1124\/dmd.109.027656_bib6","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/jm701192w","article-title":"Characterization of the drug binding specificity of rat liver fatty acid binding protein","volume":"51","author":"Chuang","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.109.027656_bib7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1124\/dmd.105.005058","article-title":"Altered AZT (3\u2032-azido-3\u2032-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment","volume":"33","author":"Engtrakul","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.027656_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.109.027656_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.plipres.2003.09.002","article-title":"Fatty acid interactions with proteins: what X-ray crystal and NMR solution structures tell us","volume":"43","author":"Hamilton","year":"2004","journal-title":"Prog Lipid Res"},{"key":"10.1124\/dmd.109.027656_bib10","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1021\/bi962018l","article-title":"Ligand binding alters the backbone mobility of intestinal fatty acid-binding protein as monitored by 15N NMR relaxation and 1H exchange","volume":"36","author":"Hodsdon","year":"1997","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.109.027656_bib11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance","volume":"47","author":"Houston","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11095-004-9015-1","article-title":"Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches","volume":"22","author":"Ito","year":"2005","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.109.027656_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0163-7258(96)00184-2","article-title":"Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data","volume":"73","author":"Iwatsubo","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.109.027656_bib14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.bcp.2005.02.020","article-title":"Electrochemical characterisation of the human cytochrome P450 CYP2C9","volume":"69","author":"Johnson","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0006-291X(90)91136-G","article-title":"Possible role of fatty-acid binding protein in the intestine as carriers of phenol and phthalate derivatives","volume":"168","author":"Kanda","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.109.027656_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2008.04.014","article-title":"In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway","volume":"76","author":"Kerdpin","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0006-3495(96)79592-9","article-title":"Characterization of the sources of protein-ligand affinity: 1-sulfonato-8-(1\u2032) anilinonaphthalene binding to intestinal fatty acid binding protein","volume":"70","author":"Kirk","year":"1996","journal-title":"Biophys J"},{"key":"10.1124\/dmd.109.027656_bib18","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: applications of in vitro and in silico modelling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.109.027656_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/bmb.2002.494030050089","article-title":"Study of protein-ligand binding by fluorescence","volume":"30","author":"Moller","year":"2002","journal-title":"Biochem Mol Biol Edu"},{"key":"10.1124\/dmd.109.027656_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0022-2275(20)31495-4","article-title":"Very long chain n-3 and n-6 polyunsaturated fatty acids binding strongly to liver fatty acid-binding protein","volume":"43","author":"Norris","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.109.027656_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.027656_bib23","doi-asserted-by":"crossref","first-page":"23918","DOI":"10.1016\/S0021-9258(19)51026-2","article-title":"Equilibrium constants for the binding of fatty acids with fatty acid binding proteins from adipocyte, intestine, heart, and liver measured with a fluorescent probe ADIFAB","volume":"269","author":"Richieri","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.027656_bib24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1124\/dmd.107.019885","article-title":"The \u201calbumin effect\u201d and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.027656_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.027656_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.027656_bib27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.027656_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0022-2836(89)90392-6","article-title":"Crystal structure of rat intestinal fatty acid binding protein. Refinement and analysis of the Escherichia coli derived protein with bound palmitate","volume":"208","author":"Sacchettini","year":"1989","journal-title":"J Mol Biol"},{"key":"10.1124\/dmd.109.027656_bib29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bcp.2003.08.025","article-title":"Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7","volume":"67","author":"Tsoutsikos","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.109.027656_bib31","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1096\/fj.99-0959com","article-title":"The intestinal fatty acid binding protein is not essential for dietary fat absorption in mice","volume":"14","author":"Vassileva","year":"2000","journal-title":"FASEB J"},{"key":"10.1124\/dmd.109.027656_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0163-7827(94)00005-7","article-title":"Cytoplasmic fatty acid binding proteins: their structure and genes","volume":"34","author":"Veerkamp","year":"1995","journal-title":"Prog Lipid Res"},{"key":"10.1124\/dmd.109.027656_bib33","doi-asserted-by":"crossref","first-page":"17769","DOI":"10.1074\/jbc.M410193200","article-title":"The interaction of lipophilic drugs with intestinal fatty acid-binding protein","volume":"280","author":"Velkov","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.027656_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chembiol.2007.03.009","article-title":"Examination of the role of intestinal fatty acid binding protein in drug absorption using a parallel artificial membrane permeability assay","volume":"14","author":"Velkov","year":"2007","journal-title":"Chem Biol"},{"key":"10.1124\/dmd.109.027656_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1018666522787","article-title":"Solution structure of human intestinal fatty acid binding protein: implications for ligand entry and exit","volume":"9","author":"Zhang","year":"1997","journal-title":"J Biomol NMR"},{"key":"10.1124\/dmd.109.027656_bib36","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00018-002-8490-y","article-title":"New insights into the structure and function of fatty acid-binding proteins","volume":"59","author":"Zimmerman","year":"2002","journal-title":"Cell Mol Life Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624020932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624020932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.109.027656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:38:49Z","timestamp":1739896729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624020932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0090955624020932"],"URL":"https:\/\/doi.org\/10.1124\/dmd.109.027656","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.109.027656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}